News about " Lawsuits and Restructuring Costs"

Bayer Warns of Higher 2025 Earnings Impact from Lawsuits and Restructuring Costs

Bayer Warns of Higher 2025 Earnings Impact from Lawsuits and Restructuring Costs

The German life sciences company now expects special items to reduce its earnings before interest, tax, depreciation, and amortisation (EBITDA) by between EUR 3.5 billion and EUR 4.0 billion, higher than the earlier forecast of EUR 2.5 billion to EUR 3.5 billion.

Lawsuits And Restructuring Costs | 13/11/2025 | By Darshana


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members